Cancer Clinical Trials
University of Maryland St. Joseph Medical Center’s (UM SJMC) Cancer Institute is an active partner in advancing the understanding and treatment of cancer through clinical trials and research studies of people who have cancer. The goal of these studies is to find better ways to treat, diagnose and prevent cancer so that people can live better and longer.
Clinical trials are the engine of cancer research and can represent a patient’s best chance for effective therapy. The clinical trials offered at UM St. Joseph Medical Center include preventive, treatment and observational research studies. They are based on nationally approved standards of cancer care and are designed to research how we can best improve our patients’ cancer outcomes.
Patients have access to national, investigator-initiated and industry-sponsored clinical trials. The UM SJMC research team can help determine if a treatment option is right for a particular patient. As with all clinical trials, patients who enroll must meet specific criteria. Here is a list of clinical trials currently in process at UM SJMC’s Cancer Institute.
A prospective study to evaluate the percent change in proliferative index (Ki67) in the primary breast tumor after neoadjuvant treatment with standard dose anastrozole or letrozole in normal, overweight, and obese patients with ER positive breast cancer (T2-3, N0/1, M0).
A randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (CTI-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.
A study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in patients with HER2+ metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting (NALA).
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of Everolimus in patients with high-risk hormone receptor-positive and HER2/neu negative breast cancer.
A phase III, randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of Lenalidomide (CC-5013) plus R-CHOP chemotherapy (R2-CHOP) versus placebo plus R-CHOP chemotherapy in subjects with previously untreated activated B-Cell Type Diffuse Large B-Cell Lymphoma.
- A randomized phase III trial of Memantine and whole-brain radiotherapy, with or without hippocampal avoidance, in patients with brain metastases.
- A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer.
ASBrS nipple-sparing mastectomy registry.
Prospective registry of multiplex testing, a research registry for people who have had a newer form of genetic testing, called multi-gene panels.
For more information about clinical trials at UM SJMC, call 410-337-4569.